References

  1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317-22. PubMed | Google Scholar

  2. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.JAMA. 2003 Apr 2;289(13):1645-51.. PubMed | Google Scholar

  3. Elion J, Labie D (1996). Bases physiopathologiques moléculaires et cellulaires du traitement de la drépanocytose. Hématologie. 1996 ; 2(6), 499-510. PubMed | Google Scholar

  4. De Mont alembert M. Stimulation de la production d'hémoglobine fœtale chez l'enfant drépanocytaire. Archives de pédiatrie. 1996; 3(3), 207-209. PubMed | Google Scholar

  5. Michaux JL, De Broe M, Van Ros G. Sickle cell anemia in Congo-Kinshasa adults. Ann Soc Belges Med Trop ParasitolMycol.1969;49(2):137-48. PubMed | Google Scholar

  6. De Montalembert M, Tshilolo L. Les progrès thérapeutiques dans la prise en charge de la drépanocytose sont-ils applicables en Afrique subsaharienne?. MedTrop (Mars). 2007Dec;67(6):612-6. PubMed | Google Scholar

  7. Mellouli F, Bejaoui M. L'utilisation de l'hydroxyurée dans les formes sévères de la drépanocytose: étude de 47 cas pédiatriques tunisiens. Arch Ped. 2008 ; 15(1), 24-28. PubMed | Google Scholar

  8. Ferster A, Vermylen C, Cornu G, Buyse M, Corazza F, Devalck C, Fondu P, Toppet M, Sariban E. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood.1996 Sep 15;88(6):1960-4. PubMed | Google Scholar

  9. De Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakjian J, Ducrocq R, Maier-Redelsperger M, Élion J, Labie D, Girot R. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J PediatrHematolOncol. 1997 Jul-Aug;19(4):313-8. PubMed | Google Scholar

  10. De Montalembert M, Bégué P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child.1999 Nov; 81(5): 437-9. PubMed | Google Scholar

  11. De Montalembert M, Bernaudin F, Bégué P, Leblanc A, Thuret I. Follow-up of a cohort of 133 children affected with sickle cell disease treated with hydroxyurea. Annual Meeting of the National Sickle Cell Program. New York City. April 14th-17th 2001. PubMed | Google Scholar

  12. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE, for the PaediatricHydroxyurea Group. Safety of Hydroxyurea in children with sickle cell anemia: result of the HUG-KIDS study, a phase I/II trial. Blood. 1999 Sep 1; 94(5):1550-4. PubMed | Google Scholar

  13. Ohene-Frempong K, Iyamu WE, Asakura T, Horiuchi K. Effect of hydroxyurea on growth of the brain and other organs in infant mice. Annual Meeting of the National Sickle Cell Program. New York City. April 14th-17th 2001. PubMed | Google Scholar

  14. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adultmen with sickle cell or myelo proliferative disease. Intern Med J. 2007 Mar; 37 (3):190-2. PubMed | Google Scholar